

Scientific Committee

Prof. Christian Kurzeder
Breast Cancer Center, University Hospital Basel
PD Dr. Marcus Vetter
Medical University Clinic, Canton Hospital Baselland

Organisation

Regula Gschwind
Breast Cancer Center, University Hospital Basel
Spitalstrasse 21, 4031 Basel
regula.gschwind@usb.ch

Speakers

Prof. Christian Kurzeder, Breast Cancer Center,
University Hospital Basel

PD Dr. Marcus Vetter, Oncology, Hematology & Immunotherapy
Medical University Clinic, Canton Hospital Baselland

Prof. Christoph Thomssen,
University Martin-Luther, Halle-Wittenberg, Germany

Dr. Andreas Gerteis, Breast Cancer Center
Hospital Robert Bosch, Stuttgart, Germany

Dr. Anton Oseledchyk, Medical Oncology,
University Hospital Basel

2 Credits SGGG

2 Credits SGMO

The certificate of participation will be sent to your personal email address after the event
(according to the guidelines of the professional societies).

University Hospital Basel

Frauenklinik
Spitalstrasse 21
4031 Basel
unispital-basel.ch



GEMEINSAM
MEHR
CHANCEN
Tumorzentrum

Brustzentrum

SB&D-03.24



3rd Swiss Annual Meeting on HER2 positive Breast Cancer

Thursday, April 11, 2024, 17.00–19.00 p.m.

University Hospital Basel
Hörsaal 1, B2, 2. Stock/Klinikum 1

Local Symposium & Webinar



**University Hospital
Basel**

Dear colleagues


The emergence of antibody-based therapies has changed our view on Her-2 overexpressing breast cancer, a story of great success that is ongoing. Most recently, HER2 directed ADCs have shown activity in HER2 negative but HER2 low breast cancer patients, and the books on classification of breast cancer need to be rewritten. With all these improvements, also new questions, challenges, and controversies arise.

This symposium has been carefully designed to bring together leading experts in the field of oncology to discuss the latest advancements and challenges in the treatment of breast cancer, with a particular focus on HER2 overexpression and HER2 low expression. The program includes a range of topics that we believe are crucial for the continued education and development of medical professionals dedicated to breast cancer care.

Again we want to present and summarize recent advances and offer a practice-focused education symposium. Eventually, we want to explore and discuss with you current treatment practice and future perspectives for the treatment of HER2 overexpressing breast cancer.

We look forward to your participation in what promises to be an enlightening and invigorating day, full of opportunities for learning and discussion.

Best regards



Prof. Christian Kurzeder
Breast Cancer Center,
University Hospital Basel



PD Dr. Marcus Vetter
Oncology, Hematology & Immunotherapy
Medical University Clinic,
Canton Hospital Baselland

Many thanks to our Partner and our Sponsors

Partner:



Main Sponsor:



Silver Sponsor:



Oncology

Bronze Sponsor:



Programme

Thursday, April 11, 2024, 17.00–19.00 p.m.

Hybrid

16.30–17.00 h	Welcome aperitif	
17.00–17.05 h	Introduction	Christian Kurzeder/ Marcus Vetter
17.05–17.30 h	Roadmap to cure in early and advanced HER2 pos. breast cancer	Christoph Thomssen
17.30–17.50 h	Adjuvant and neoadjuvant therapy in HER2 breast cancer - a critical reappraisal	Andreas Gerteis
17.50–18.10 h	Best sequencing strategies in HER2 pos. and HER2 low advanced breast cancer - HR pos. and HR neg. disease	Marcus Vetter
18.10–18.30 h	Modern therapeutic approaches to brain metastases and leptomeningeal disease	Christian Kurzeder
18.30–18.50 h	The ABC of ADCs – Considerations on toxicity management	Anton Oseledchyk
18.50–19.00 h	Panel discussion	Christian Kurzeder/ Marcus Vetter

Registration is required

To attend this event in **person (OnSite)**, please register to: regula.gschwind@usb.ch

To attend this event **online**, please register using the following link:



[online registration](#)

After registration, the access link will be sent to you automatically by e-mail.